Kalaris Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative treatments for prevalent retinal diseases. The company's scientific foundation is built on the pioneering research of co-founder Dr. Napoleone Ferrara, whose previous work led to the development of anti-VEGF therapy. Kalaris's lead investigational asset is TH103, a novel, fully humanized recombinant fusion protein designed as a decoy receptor (VEGF trap). TH103 is engineered to achieve extended intraocular retention and enhanced VEGF inhibition, targeting major sight-threatening conditions such as neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO). Kalaris transitioned to a public company in March 2025 through a reverse merger with AlloVir, Inc..
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical evaluation of lead asset TH103, a novel dual-targeting VEGF/HSPG recombinant fusion protein designed for extended intraocular retention and enhanced VEGF inhibition.
Expected impact: Establish a potential best-in-class, longer-lasting therapy for neovascular Age-related Macular Degeneration (nAMD) to reduce patient injection burden.
Completion of new manufacturing batches of TH103 drug product incorporating process improvements.
Expected impact: Further reduction of already low levels of process impurities, enhancing product quality and regulatory confidence for upcoming clinical dosing.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Kalaris with the foundational patent rights and know-how for the technology used to develop its lead product candidate, TH103.
Terms: Kalaris pays annual license maintenance fees (e.g., $10,000 expensed in 2024) and is obligated to pay milestone payments and royalties on future net sales.
Redeemed 50,000 shares of founder's restricted stock in exchange for a future royalty stream, aligning interests with its founding venture investor.
Terms: Kalaris agreed to pay Samsara a low single-digit percentage tiered royalty on future net sales of products developed under the licensed UCSD technology.